Search for dissertations about: "Amyloid Detection in dementia"
Showing result 1 - 5 of 14 swedish dissertations containing the words Amyloid Detection in dementia.
-
1. Characterization of [18F]flutemetamol binding properties : A β-amyloid PET imaging ligand
Abstract : The criteria for diagnosing Alzheimer’s disease (AD) have recently been revised to include the use of biomarkers for the in vivo presence of β-amyloid, one of the neuropathological hallmarks of AD. Examples of such biomarkers are positron emission tomography (PET) β-amyloid specific ligands, including [18F]flutemetamol. READ MORE
-
2. Neuroinflammation in Alzheimer's disease : Focus on NF-κB and C/EBP transcription factors
Abstract : Alzheimer's disease (AD) is the most common form of dementia among elderly. The disease is characterized by amyloid-β (Aβ) plaques, neurofibrillary tangles, loss of synapses and neurons and chronic neuroinflammation. READ MORE
-
3. Microvascular disease in cognitive impairment
Abstract : Background: Cerebral small vessel disease has been recognized as the greatest vascular contributor to dementia. Previously, small vessel disease was thought to be part of normal aging. READ MORE
-
4. Proteomic strategies for analysis of cerebrospinal fluid in neurodegenerative disorders
Abstract : ABSTRACT There is a great need for biomarkers to diagnose neurodegenerative disorders, such as the cognitive disorders Alzheimer?s disease (AD) and frontotemporal dementia (FTD). Cerebrospinal fluid (CSF) is in contact with the extracellular fluid of the brain and is consequently a valuable medium for identifying biomarkers for neurological disorders. READ MORE
-
5. Amyloid imaging in Alzheimer’s disease and mild cognitive impairment by positron emission tomography
Abstract : Effectiveness of future treatment strategies in Alzheimer s disease (AD) will rely on early detection of disease and the possibility to clearly evaluate their effects. The findings presented in this thesis concerns both early in vivo detection of amyloid deposition in the brains of patients at risk of developing AD and the longitudinal changes of pathological and functional parameters in patients with AD. READ MORE